Announcement on Authorizing the Chairman of the Company to Use Its Own Funds for Entrusted Financial Management
Release time:
2020-08-05
Securities Abbreviations: Jianfeng Group Securities Code: 600668 Number: Pro 2019-012
Bond Abbreviations: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Authorizing the Chairman of the Company to Use Its Own Funds to Entrust Financial Management
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents .
Important Content Reminder:
● Entrusted Wealth Management Amount: Authorizes the Chairman of the Board to exercise the decision-making power of entrusted wealth management not exceeding RMB billion, within which funds can be used on a rolling basis, however, the total entrusted financial balance of surviving at any point in time shall not exceed 5 .4 billion yuan.
● Entrusted Wealth Management Investment Type: Select varieties with high security, good liquidity and low risk to carry out entrusted wealth management business.
● Entrusted financial management period: the period of each investment business shall not exceed 12 months.
1. overview
(I) basic situation
1 , principle: take "standard operation, risk prevention, prudent investment, value preservation and appreciation" as the principle.
2 , Varieties: Select varieties with high security, good liquidity and low risk to carry out entrusted wealth management business.
3 . Funds: own funds.
4 , authorized amount and term: the chairman of the board of directors is authorized to exercise the decision-making power of entrusted financial management not exceeding RMB 5 .3 billion yuan. within the amount, the funds can be used on a rolling basis, but the total balance of entrusted financial management existing at any time point shall not exceed RMB 5 .5 billion yuan. The term of each entrusted financial management shall not exceed 12 months. The authorization period shall be valid for 3 years from the date of approval by the Board of Directors of the Company. The specific investment activities are organized and implemented by the Company's Finance Department.
5 , Implementation Method: Authorize the chairman of the board to decide on matters related to entrusted financial investment within the above amount, including but not limited to: selecting qualified professional financial institutions, selecting specific types of entrusted financial products, specifying the amount and term of entrusted financial management, signing relevant contracts and agreements, etc.
(II) the approval procedures to be performed within the company
2019 , Zhejiang Jianfeng Group Co., Ltd. held the 106 meeting of the 10th board of directors, of which eight directors attended the meeting in person, director Du Zihong entrusted Director Jiang Xiaomeng to attend the meeting and vote on on his behalf. complies with the relevant provisions of the "Company Law" and the company's "Articles of Association", and the resolutions made are legal and valid. The meeting was presided over by Chairman Jiang Xiaomeng. After deliberation and voting, with 9 votes in favor, 0 votes against, and 0 abstentions, the "Proposal on Authorizing the Chairman of the Company to Use Its Own Funds for Entrusted Financial Management " was deliberated and passed.
2. Main Contents
(I) Entrusted Funds Source: Own Funds .
Impact of (II) on the Company
1 . The entrusted financial management of the Company is implemented on the premise of ensuring the daily operation and capital safety of the Company, and does not affect the daily capital turnover of the Company or the normal development of the Company's business.
2 . Through moderate and low-risk financial product investment business, we can improve the efficiency of capital use, obtain certain investment benefits, and seek more investment returns for the company's shareholders.
(III) Risk Control Analysis
Company strictly follows the approval and implementation procedures of "Entrusted Financial Management System" to ensure the effective development and standardized operation of entrusted financial management and other investment businesses. However, as the financial market is greatly affected by the economic environment, it is not ruled out that investment businesses such as investment and wealth management will be affected by market fluctuations. The company will take the following measures:
( 1 ) The company will clearly assign special personnel to be responsible for the relevant work of such investment matters: the chairman of the company exercises the investment decision-making power and signs relevant contract documents, the company's financial director is responsible for organizing the implementation, and the finance department is responsible for the specific operation.
( 2 ) The company's finance department is responsible for timely analyzing and tracking the investment direction of financial products and the progress of investment projects. If the evaluation finds that there are conditions that may affect the company's capital security or affect the normal capital flow demand, corresponding preservation or redemption measures will be taken in time to control investment risks.
( 3 ) The audit department of the company is responsible for auditing and supervising various investments, and regularly auditing and verifying the progress, profit and loss, and risk control of entrusted financial management. According to the principle of prudence, evaluate the possible risks and benefits of various entrusted financial management and report to the audit committee of the board of directors.
( 4 ) The company fulfills its information disclosure obligations in strict accordance with the relevant regulations of the China Securities Regulatory Commission and the Shanghai Stock Exchange.
(IV) Independent Director Opinion
The independent director of the company issued an independent opinion on the resolution, and believed that: the company's entrusted financial management is implemented on the premise of ensuring the company's daily operation and capital safety. It does not affect the company's daily capital turnover and does not affect the normal development of the company's business operations. By carrying out moderate low-risk financial product investment business, we can improve the efficiency of capital use, obtain certain investment benefits, and seek more investment returns for the company's shareholders.# The 174 has not found any damage to the rights and interests of the company and small and medium-sized shareholders. Agree to authorize the chairman to use his own funds for entrusted financial management.
"Announcement on the Progress of Entrusted Financial Management" on 2019 . As of the date of this announcement, the company has recovered all the entrusted financial management due.
As of the date of this announcement, the company's accumulated amount of entrusted financial management is 2.5 .4 billion yuan. See the following table for details:
| Trustee
| Financial Product Type
| Amount
(RMB 10,000)
| Start Date
| Due Date
|
Deadline Announcement Date recovered principal amount (RMB 10,000)
|
income as of the announcement date (RMB 10,000)
|
| 1
| Bank of Communications Jinhua Branch
|
Yuntong Wealth Fixed Term Structured Deposit
|
3,000.00
|
2019/2/1
|
2019/6/6
|
/
|
/
|
| 2
| Guangfa Bank Jinhua Branch
|
Salary Increase 16 RMB structured deposit product
|
5,000.00
|
2019/2/20
|
2019/5/21
|
/
|
/
|
|
Agricultural Bank of China Jinhua Jiangbei Sub-branch
|
Huili Feng 2019 4505 Issue Customized RMB Structured Deposit Product
|
5,000.00
|
2019/2/22
|
2019/5/24
|
/
|
/
|
4
|
Guangfa Bank Jinhua Branch
|
Salary Increase 16 RMB Structured Deposit Product
|
4,000.00
|
2019/4/9
|
2019/7/8
|
/
|
/
|
5
|
Bohai Bank Jinhua Branch
|
Bank Bohai S190534 Structured Deposit Financial Product
|
4,000.00
|
More information
Pharmaceutical Company Established New Drug R & D Promotion Committee
Recently, the new drug research and development promotion committee of Jianfeng pharmaceutical company was formally established, which will be responsible for promoting the new drug research and development progress of pharmaceutical companies and subordinate enterprises, and coordinating the new drug research and development work of various departments and subordinate enterprises. The New Drug Promotion Committee is headed by Huang Jinlong, deputy general manager of the group and general manager of the pharmaceutical company, and Jiang Hong, deputy general manager of the pharmaceutical company, is headed by Pang Xiong, Shi Cunyuan, Xu Lizhen, Yu Jingjing, Zheng Kunwu, Feng Lixiang, Kang Litao, Li Qian, Wu Chonggui, Zhai Tsunami, Huang Fang and Tong Xiaojun. The committee has an office, and Shi Cunyuan is also the director of the office, responsible for the supervision, communication, and coordination of the company's new drug research and development projects. The main responsibilities of the new drug promotion committee include: organizing the establishment and improvement of the R & D project management system and relevant regulations of the pharmaceutical company; organizing the formulation of the development plan of the new drug R & D project of the pharmaceutical company and supervising the implementation; making decisions on project initiation and participating in project evaluation; supervising the management of new drug R & D of the pharmaceutical company and providing guidance; Responsible for the process management of new drug R & D projects and the promotion and coordination of new drug R & D; carry out the assessment of new drug research and development projects; issue the responsibility system assessment and task statement of new drug research and development projects; be responsible for solving major technical problems in the process of new drug research and development; be responsible for the research and improvement of the management mode of research and development projects of pharmaceutical companies; be responsible for the future trend analysis of new drug research and development projects; review the major scientific research achievements of pharmaceutical companies and put forward reward suggestions. Huang Jinlong said that the research and development of new drugs is an important foundation for the healthy development of the pharmaceutical industry and is a systematic project. Jianfeng Pharmaceutical has always attached great importance to the research and development of new drugs, but there is still a certain gap between the progress of research and development and the development process of the enterprise, and the lack of coordination in the research and development process also affects the progress and quality of new drug research and development to a certain extent. The purpose of the establishment of the New Drug Research and Development Promotion Committee is to solve the progress of new drug research and development, to find and solve problems in time, to implement more targeted, and to effectively integrate enterprise resources, improve the speed and quality of new drug research and development, and make good product reserves for the healthy development of pharmaceutical companies. (Reporter Ni Yingzhen)
2020
09-11
Jianfeng Pharmaceutical ranks among the top 100 Chinese pharmaceutical industries in 2019
On August 25, the "2019 Top 100 Series List of China's Pharmaceutical Industry" was released in Kunming. Zhejiang Jianfeng Pharmaceutical Company was shortlisted as one of the top 100 enterprises in China's pharmaceutical industry. The product Berunning (Olopatadine Hydrochloride Eye Drops) was selected as the "Most Growing Product Brand" of China's pharmaceutical industry ". The "Top 100 Pharmaceutical Industry Series List" was evaluated and released by Guangzhou Punctuation Pharmaceutical Information Co., Ltd., a subsidiary of the Southern Institute of Pharmaceutical Economics of the State Drug Administration, and is known as the "Oscar in Chinese Pharmaceutical Industry. Southern Institute is the earliest institution in China that specializes in pharmaceutical industry policy and market economy research, pharmaceutical market research, pharmaceutical economic data analysis and research, and pharmaceutical professional media publishing. It is in the field of market information value-added services and media communication and marketing services in China's pharmaceutical and health industry., The field of professional quality improvement has extremely extensive influence. The "Top 100 Pharmaceutical Industry" is comprehensively evaluated by the company's annual pharmaceutical industry sales revenue, total profit and R & D investment results. On the same day, the "most growing product brand" of Chinese medicine selected by the Southern Institute's media "Pharmaceutical Economic News" was released simultaneously. Spike Pharmaceuticals product Beirunning (Olopatadine Hydrochloride Eye Drops) was selected. (Xu Yuting)
2020
09-01
Company Disclosure 2020 Semi-Annual Report
On August 28, the Group held the 16th meeting of the 10th Board of Directors of the Company by means of communication, and considered and adopted the "2020 Semi-Annual Report of Jianfeng Group" and the "Proposal on Changes in the Company's Accounting Policy". On August 29, the Company's 2020 semi-annual report was publicly disclosed on the Shanghai Stock Exchange and the Shanghai Securities News and China Securities News. In the first half of the year, the Group focused on the general policy of "grasping projects, making up for shortcomings, improving quality and efficiency, and constantly improving the core competitive advantage", and on the basis of doing a good job in epidemic prevention and control, the Group seized the resumption of work and production, accelerated project construction, and enhanced the core competitiveness of enterprises. In the first half of 2020, the company achieved total operating income of 1.44 billion yuan, net profit attributable to shareholders of 0.368 billion yuan, net profit per share of 1.07 yuan. As of the end of June 2020, the Company's total assets were $5.892 billion, net assets were $4.068 billion, and net assets per share were $11.82. From February to April, affected by the epidemic, the national project construction progress slowed down, cement market demand decreased; after May, the epidemic was effectively controlled, infrastructure investment continued to recover, the real estate industry continued to pick up, cement sales steadily rebounded. During the outbreak, Daye Peak completed the technical transformation projects such as the cold machine, cement mill, into the desulfurization tower anti-corrosion transformation, to ensure the efficient operation of the production equipment after the resumption of work. Yunnan peak rotary kiln production, cement production and other major technical and economic indicators of steady rise; comply with market trends, timely adjustment of marketing policies. Guizhou Jianfeng has promoted the project infrastructure construction, equipment installation and commissioning, raw material bidding and other work in an orderly manner, and through preliminary publicity to enhance the popularity of the Jianfeng brand in the local area, and make a series of preparations for the transformation from project construction to production and operation. In the first half of 2020, the reform of China's medical and health system continued to deepen, and new policies were introduced intensively. Peak Pharmaceuticals and its subsidiaries in the epidemic prevention work at the same time in the first time to achieve the resumption of production, and actively organize donations to support the fight against the epidemic, was named the annual "war epidemic star" the most socially responsible pharmaceutical enterprises. In the first half of the year, Jianfeng Pharmaceutical continued to increase the introduction and development of varieties, and JFAN-1001 applied for clinical application of new anti-tumor drugs. At present, it has obtained the notice of approval for clinical trials. Optimize the production process of API workshop and further shorten the production cycle of raw materials. Continue to improve product sales policies and strengthen market channel control. Shanghai North Carolina further straightened out the internal management structure, production and marketing convergence more smoothly, continue to promote the construction of Anhui North Carolina and Anhui Zhongwang Phase II technical transformation project, promote the peak pharmaceutical raw materials, preparations integration of industrial upgrading strategy. Other business segments of the company actively responded to the challenge of the new crown epidemic and carried out production and operation activities in a standardized and orderly manner. Tianjin natural products company vigorously explore the international and domestic markets, sales revenue to achieve steady growth. Peak Health focuses on the basic idea of "sales orientation, burden reduction and efficiency improvement, fine-grained savings, cost reduction and efficiency enhancement" to effectively improve the operational efficiency of enterprises. Jianfeng International Trade has actively developed new storage business varieties and achieved practical results, and has become the first enterprise in Jinhua to formally obtain the qualification of "network freight. Peak cable seizes the special needs of communication cables such as subways, vigorously promotes large logarithmic cables for subways, and strives to achieve the long tail effect. On the same day, the company also held the 10th meeting of the Ninth Board of Supervisors and reviewed and approved relevant reports. (residual fruit)
2020
09-01
The company organizes new employee induction training
From August 12 to 14, in order to strengthen the training of talents in the group and improve the comprehensive quality of new employees, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, Yu Jianhong, general manager, and other leaders and heads of relevant enterprises and departments conducted a three-day induction training for new employees. New employees from foreign enterprises such as Guizhou Huangping Peak, Daye Peak and Shanghai North Carolina participated simultaneously through online methods. In the course of corporate culture, General Manager Yu Jianhong started from the history of the development and struggle of the peak, divided into five stages: hard work, determined reform, diversified development, strategic adjustment, and strategic development, and introduced in detail the development process of the group company and the current industrial layout., The results achieved; from the aspects of enterprise spirit, vision, development philosophy, values, business philosophy, etc, this paper introduces the peak corporate culture rooted in 62 years of history and inherited in the blood; from the perspective of an enterprise manager and old employees, he speaks a lot of truth to the new employees and puts forward a lot of hopes and suggestions. Chairman Jiang Xiaomeng took "How New Employees Achieve Win-Win with Enterprises" as the topic, and proposed that the key to the success of an enterprise lies in how to select, retain, educate and employ people. Peak and employees complement each other. Peak can achieve today's achievements and the struggle of generations of peak people are inseparable. He also taught new employees the basic concepts that need to be understood, the basic qualities that need to be possessed and the sense of hardship in entering the new environment through 16 key words, and combined with his own experience and quoting from others, he analyzed the core elements of success, the signs of a successful career, the personal qualities that need to be possessed for success, and the importance of establishing a personal knowledge management system, it expresses the ardent hope of new employees to adjust their mentality, keep learning, clear goals, clear dreams, cultivate win-win thinking, and grow up together with the peak. The heads of the human resources department of the group company, the safety management office of the group company, and the comprehensive department of the pharmaceutical company also taught the new employees the corporate rules and regulations and the "Employee Handbook", safety knowledge and professional ethics. The new employees also visited the group exhibition hall and had a deeper understanding of the development history and enterprise achievements of the peak. After the training, the human resources department also organized an examination to test the training effect. (Reporter Chen Shengmu)
2020
08-21
According to this newspaper, through the interconnection monitoring of the transportation department in Zhejiang province, the network freight platform of peak international trading company passed the online service capability audit, interface access audit, eight capability identification and other audit procedures, and successfully obtained the road transportation business license with the qualification of "network freight" on July 2. It is understood that Jianfeng International Trade is currently the first enterprise in Jinhua and Quzhou to obtain this qualification.
2020
08-05
News from our newspaper On July 21, Xi Jinping, General Secretary of the Central Committee of the Communist Party of China, President of the State, and Chairman of the Central Military Commission hosted a symposium for entrepreneurs in Beijing and delivered an important speech. Over the past few days, the General Secretary's speech has aroused strong repercussions in all walks of life. On July 23, Jiang Xiaomeng, chairman of the group company, said in an interview with Jinhua TV that the general secretary's speech was calm and inspiring, and pointed out the direction of future work for entrepreneurs.
2020
08-05